Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.
MetadataShow full item record
BACKGROUND: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants via routine datasets could provide a cost-effective alternative for ascertaining follow-up information required to evaluate disease outcomes. This project explores the potential for routine data to inform cancer trials, using, the historical National Cancer Data Repository (NCDR) for English NHS sites and, for validation, mature data available from the TACT trial. METHODS: Datasets were matched using patients' NHS number, date of birth (dob) and name/initials. Demographics, clinical characteristics and outcomes were assessed for agreement and completeness. Overall survival was compared between NCDR and TACT. RESULTS: A total of 3151 patients underwent linkage; 3047 (96.7%) of which had matched records. Extensive cleaning was required for some registry data fields, e.g. cause of death, whilst others had large amounts of missing data, e.g. tumour size (22.1%). Other data had high levels of matching such as dob (99.6%) and date of death (89.6%). There was no evidence of differential survival rates (8-year survival: TACT = 75% (95% CI 73, 76); NCDR = 76% (95% CI 74, 77)). CONCLUSIONS: Data quality and completeness requires improvement before routine data could be used for RCTs. Introduction of new routine datasets, including COSD, is welcomed although reporting of disease-recurrence events remains a concern. Prospective validation of such datasets is required before RCTs can confidently switch patient follow-up to utilise routinely collected NHS-based data. TACT TRIAL REGISTRATION: Clinicaltrials.gov NCT00033683 , registered on 9 April 2002; ISRCTN79718493 , registered on 1 July 2001.
Version of record
Randomised controlled trial
Routine data linkage
Antineoplastic Combined Chemotherapy Protocols
Health Services Research
Medical Record Linkage
Randomized Controlled Trials as Topic
Reproducibility of Results
Clinical Trials & Statistics Unit
License start date
Trials, 2017, 18 (1), pp. 561 - ?
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Holyoake, DL; Ward, E; Grose, D; McIntosh, D; Sebag-Montefiore, D; Radhakrishna, G; Patel, N; Silva, M; Mukherjee, S; Strauss, VY; Odondi, L; Fokas, E; Melcher, A; Hawkins, MA (2016-01)Standard therapy for borderline-resectable pancreatic cancer in the UK is surgery with adjuvant chemotherapy, but rates of resection with clear margins are unsatisfactory and overall survival remains poor. Meta-analysis ...
Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Kühnl, A; Cunningham, D; Counsell, N; Hawkes, EA; Qian, W; Smith, P; Chadwick, N; Lawrie, A; Mouncey, P; Jack, A; Pocock, C; Ardeshna, KM; Radford, J; McMillan, A; Davies, J; Turner, D; Kruger, A; Johnson, PW; Gambell, J; Rosenwald, A; Ott, G; Horn, H; Ziepert, M; Pfreundschuh, M; Linch, D (2017-07-01)Background: There is an on-going debate whether 2- or 3-weekly administration of R-CHOP is the preferred first-line treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL). The UK NCRI R-CHOP14v21 randomized ...
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Vormoor, B; Veal, GJ; Griffin, MJ; Boddy, AV; Irving, J; Minto, L; Case, M; Banerji, U; Swales, KE; Tall, JR; Moore, AS; Toguchi, M; Acton, G; Dyer, K; Schwab, C; Harrison, CJ; Grainger, JD; Lancaster, D; Kearns, P; Hargrave, D; Vormoor, J (2017-06)Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and ...